Biotech Late Stage Investors & VC Firms
652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.
CPT Capital
LondonPre-Seed–Late Stage
8 people
Crossbeam Venture Partners
New YorkPre-Seed–Late Stage$1M – $1.5M
5 people
Narya Capital
ColumbusPre-Seed–Late Stage
5 people
OCV Partners
Los AngelesPre-Seed–Late Stage
5 people
Access Biotechnology
New York CitySeed–Late Stage
2 people
Mithril Capital Management
AustinSeries B–Late Stage
2 people
Fresenius Medical Care Ventures
Bad HomburgSeed–Late Stage
7 people
Kolon Investment, Inc.
SeoulSeed–Late Stage$3K – $22M
KIC Ventures
Fort LauderdaleSeed–Late Stage
10 people
Pandect Bioventures
WoodsideSeed–Late Stage
10 people
Fengate Private Equity
TorontoGrowth–Late Stage
11 people
Vesalius Biocapital Partners
LuxembourgSeed–Late Stage$11M
5 people
Waarde Capital
CapellenPre-Seed–Late Stage$15M
5 people
Artiman Ventures
Palo AltoSeed–Late Stage$2M – $6M
10 people
HighCape Capital
WestportSeries C–Late Stage
7 people
Deep Insight
Tel AvivPre-Seed–Late Stage
6 people
Ming capital
ShenzhenSeed–Late Stage
6 people
SIDBI Venture Capital
MumbaiSeed–Late Stage
6 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
6 people
Yali Capital
BengaluruPre-Seed–Late Stage
9 people
Fundamental Ventures
LakewayPre-Seed–Late Stage
2 people
H Venture Partners
CincinnatiSeed–Late Stage$250K – $5M
2 people
Quest for Growth
LeuvenGrowth–Late Stage
10 people
Unfold Ventures
WrocławPre-Seed–Late Stage$110K – $1.1M
7 people
Related lists
Late Stage Investors & VC Firms (2974)Biotech Investors & VC Firms (2185)Biotech Seed Investors & VC Firms (1824)Late Stage Investors & VC Firms in North America (1695)Biotech Series A Investors & VC Firms (1668)Late Stage Investors & VC Firms in United States (1516)Biotech Investors & VC Firms in North America (1391)Biotech Investors & VC Firms in United States (1267)Late Stage Investors & VC Firms in Europe (965)Biotech Pre-Seed Investors & VC Firms (957)
Data sourced from public filings and firms' own websites — see our methodology.







































































